China’s BVCF Targets $400 Million For Fourth Fund

BVCF (BioVeda China Fund), a Shanghai-based private equity and venture investment firm focused on life sciences, is targeting US$400 million for its fourth U.S. dollar fund and is expecting a first close in a few months, according to someone familiar with the matter.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

China Expert network